Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 240 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Malabsorption Clear all
Terminated No phase listed Observational

Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting

NCT02036944
View directory record Official record
Conditions
Celiac Disease, Iron Deficiency, Iron Malabsorption
Interventions
Not listed
Lead sponsor
Providence Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

NCT02734810
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase Powder for Oral Solution
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
28 Days and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
21
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 18, 2026, 1:08 AM EDT
Not listed Phase 1Phase 2 Interventional

Proof of Concept Study in Patients With Short Bowel Syndrome

NCT04379856
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NM-002
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Results available

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

NCT03486990
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 18, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

NCT04988997
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Vurolenatide 50mg/PBO, Vurolenatide 100mg/PBO, Vurolenatide 50/50 mg, Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Gainesville, Florida • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Results available

Assessment of KAN-101 in Celiac Disease (ACeD)

NCT04248855
View directory record Official record
Conditions
Celiac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Anaheim, California • Walnut Creek, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 18, 2026, 1:08 AM EDT
Completed No phase listed Observational

Assessment of Duodenal Epithelial Integrity in Celiac Disease With Mucosal Impedance

NCT03152279
View directory record Official record
Conditions
Celiac Disease
Interventions
Mucosal Impedance Catheter, Blood sample
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

NCT00492960
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate, placebo, 900 mg gluten
Drug · Dietary Supplement
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 18, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vedolizumab Induction May Prevent Celiac Enteritis

NCT02929316
View directory record Official record
Conditions
Celiac Disease
Interventions
Vedolizumab
Drug
Lead sponsor
AGA Clinical Research Associates, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 18, 2026, 1:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome

NCT03051204
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Celiac Disease, Healthy
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 18, 2026, 1:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Foods on Bile Acids, Metabolites, and Inflammation

NCT05245357
View directory record Official record
Conditions
Inflammation, Hypertriglyceridemia, Metabolic Disease, Lipid Metabolism Disorder, Hyperlipidemias, Bile Acid Malabsorption
Interventions
Lentil, Control
Behavioral
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

NCT00572975
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 18, 2026, 1:08 AM EDT
Active, not recruiting Early Phase 1 Interventional

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

NCT06326645
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Crofelemer Oral Product
Drug
Lead sponsor
Jessica Sosio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Raw Versus Other Milk Sources on Lactose Digestion

NCT01129791
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Raw Milk, Pasteurized Milk, Non-dairy milk
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 18, 2026, 1:08 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Responses to Gluten

NCT05209568
View directory record Official record
Conditions
Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Interventions
Gluten Powder
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 101 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Not applicable Interventional Results available

Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

NCT01930539
View directory record Official record
Conditions
Vitamin D Deficiency, Short Bowel Syndrome
Interventions
Ultraviolet B lamp
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 18, 2026, 1:08 AM EDT
Recruiting Phase 2 Interventional

Study of DONQ52 in Active Celiac Disease

NCT07239336
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
Drug · Dietary Supplement
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
58
States / cities
Anniston, Alabama • Homewood, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 2 Interventional

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

NCT05636293
View directory record Official record
Conditions
Celiac Disease
Interventions
Ritlecitinib, Placebo, Gluten
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 3 Interventional

Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

NCT03597516
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebos
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Chula Vista, California • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 18, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia

NCT00399191
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
stable isotope of iron, dysprosium
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 18, 2026, 1:08 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

NCT02510560
View directory record Official record
Conditions
Premature Birth of Newborn, Intestinal Malabsorption
Interventions
NTRA-2112, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
1 Day to 5 Days
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Greenville, North Carolina • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 18, 2026, 1:08 AM EDT
Completed No phase listed Observational

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

NCT05686369
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 18, 2026, 1:08 AM EDT